|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:NantKwest
|
|
gptkbp:CEO
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:clinicalTrialPhase
|
pancreatic cancer
bladder cancer
COVID-19 vaccine candidates
|
|
gptkbp:collaboratesWith
|
gptkb:National_Cancer_Institute
gptkb:Fred_Hutchinson_Cancer_Research_Center
|
|
gptkbp:developedBy
|
cell-based therapies
immunomodulators
vaccine candidates
|
|
gptkbp:focusesOn
|
infectious diseases
oncology
immunotherapy
|
|
gptkbp:foundedYear
|
2014
|
|
gptkbp:founder
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:headquartersLocation
|
gptkb:Culver_City,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ImmunityBio
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:notableProduct
|
gptkb:Anktiva_(N-803)
gptkb:QUILT_clinical_trial_platform
|
|
gptkbp:numberOfEmployees
|
500-1000
|
|
gptkbp:parentCompany
|
gptkb:NantWorks
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:IBRX
|
|
gptkbp:website
|
https://www.immunitybio.com/
|
|
gptkbp:bfsParent
|
gptkb:NantKwest
|
|
gptkbp:bfsLayer
|
6
|